"Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study."
PHASE4RecruitingINTERVENTIONAL
Enrollment
25
Participants
Timeline
Start Date
January 10, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG
Methylnaltrexone
Given by SC (injection)
Trial Locations (1)
77030
RECRUITING
MD Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT06162377 - "Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study." | Biotech Hunter | Biotech Hunter